Live Yum Brands Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Entero Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Entero Therapeutics, Inc.

ENTO

Entero Therapeutics, Inc.

About Entero Therapeutics, Inc.

Entero Therapeutics, Inc. develops targeted, non-systemic therapies for gastrointestinal diseases, focusing on locally acting biologics like Adrulipase for exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis. The company advances its products through clinical trials, leveraging proprietary enzymes and formulations, and operates in regulated markets worldwide. It emphasizes innovative drug delivery, intellectual property protection, and strategic collaborations within the biopharmaceutical industry.
This description was generated via AI from an annual report. Updated 10 months ago.

Latest SEC Filings from Entero Therapeutics, Inc.

1
1
Entero Therapeutics, Inc. GridAI Technologies Reports $3.4 Million Net Loss in Q1 2026, First Revenue Since Acquisition

Via official filing (AI summary) | about 2 months ago | 0 comments

2
1
Entero Therapeutics, Inc. GridAI Technologies Corp. Reports $36.3M Revenue in Transition to Energy Technology

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Entero Therapeutics, Inc. Entero Therapeutics Reports Q3 2025 Financial Results with Reduced Losses and Increased Cash Reserves

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
Entero Therapeutics, Inc. Entero Therapeutics Reports Significant Reduction in Operating Expenses and Net Losses for Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
Entero Therapeutics, Inc. Entero Therapeutics Reports $1.26 Million Net Loss and Significant Expense Reductions in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Entero Therapeutics, Inc. Entero Therapeutics Reports $18.1 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Entero Therapeutics, Inc. Entero Therapeutics Reports Improved Financials, Shifts Focus After ImmunogenX Acquisition

Via official filing (AI summary) | over 1 year ago | 0 comments

8
1
Entero Therapeutics, Inc. Entero Therapeutics Reports Significant Asset Growth, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments